《大行報告》高盛降港交所(00388.HK)目標價至351元 收窄股票買賣差價利增交投
高盛證券發表報告,預期本港股票市場日均成交量經過兩年下跌後,明年將會回升,不過市場復甦需要宏觀環境或政策轉變帶來的催化劑,而目前尚未看到。港交所業務的亮點,是本港上市衍生工具的日均交易量增加,以及LME帶動日均成交量增長,加上投資收入上升,部分抵銷港股日均成交下跌的影響,該行預期港交所今年收入按年上升約10%,每股盈利上升約16%。
該行指,本港股份買賣差價較全球其他可比較市場為高,當局檢討收窄買賣差價,有助減低交易成本,將會是明年推升成交量的催化劑,該行溫和下調港交所2023-26年每股盈測1%至3%,目標價相應由361元降至351元,評級則為「買入」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.